A phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with locally advanced pancreatic cancer - PubMed

Clinical Trial

A phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with locally advanced pancreatic cancer

M Ikeda et al. Br J Cancer. 2002.

Abstract

This study investigated the maximum-tolerated dose of gemcitabine based on the frequency of dose-limiting toxicities of weekly gemcitabine treatment with concurrent radiotherapy in patients with locally advanced pancreatic cancer. Fifteen patients with locally advanced pancreatic cancer that was histologically confirmed as adenocarcinoma were enrolled in this phase I trial of weekly gemcitabine (150-350 mg x m(-2)) with concurrent radiotherapy (50.4 Gy in 28 fractions). Gemcitabine was administered weekly as an intravenous 30-min infusion before radiotherapy for 6 weeks. Three of six patients at the dose of 350 mg x m(-2) of gemicitabine demonstrated dose-limiting toxicities involving neutropenia/ leukocytopenia and elevated transaminase, while nine patients at doses of 150 mg x m(-2) and 250 mg x m(-2) did not demonstrate any sign of dose-limiting toxicity. Of all 15 enrolled patients, six patients (40.0%) showed a partial response. More than 50% reduction of serum carbohydrate antigen 19-9 level was observed in 13 (92.9%) of 14 patients who had pretreatment carbohydrate antigen 19-9 levels of 100 U x ml(-1) or greater. The maximum-tolerated dose of weekly gemcitabine with concurrent radiotherapy was 250 mg x m(-2), and this regimen may have substantial antitumour activity for patients with locally advanced pancreatic cancer. A phase II trial of weekly gemcitabine at the dose of 250 mg x m(-2) with concurrent radiation in patients with locally advanced pancreatic cancer is now underway.

Similar articles

• Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas.

  Pipas JM, Mitchell SE, Barth RJ Jr, Vera-Gimon R, Rathmann J, Meyer LP, Wagman RS, Lewis LD, McDonnell C, Colacchio TA, Perez RP. Pipas JM, et al. Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1317-22. doi: 10.1016/s0360-3016(01)01580-2. Int J Radiat Oncol Biol Phys. 2001. PMID: 11483344 Clinical Trial.

• Estimating optimal dose of twice-weekly gemcitabine for concurrent chemoradiotherapy in unresectable pancreatic carcinoma: mature results of GEMRT-01 Phase I trial.

  Girard N, Mornex F, Bossard N, Ychou M, Chauffert B, Wautot V. Girard N, et al. Int J Radiat Oncol Biol Phys. 2010 Aug 1;77(5):1426-32. doi: 10.1016/j.ijrobp.2009.06.053. Epub 2010 Jan 7. Int J Radiat Oncol Biol Phys. 2010. PMID: 20056351 Clinical Trial.

• Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial.

  Small W Jr, Berlin J, Freedman GM, Lawrence T, Talamonti MS, Mulcahy MF, Chakravarthy AB, Konski AA, Zalupski MM, Philip PA, Kinsella TJ, Merchant NB, Hoffman JP, Benson AB, Nicol S, Xu RM, Gill JF, McGinn CJ. Small W Jr, et al. J Clin Oncol. 2008 Feb 20;26(6):942-7. doi: 10.1200/JCO.2007.13.9014. J Clin Oncol. 2008. PMID: 18281668 Clinical Trial.

• Combining gemcitabine with radiation in pancreatic cancer: understanding important variables influencing the therapeutic index.

  Crane CH, Wolff RA, Abbruzzese JL, Evans DB, Milas L, Mason K, Charnsangavej C, Pisters PW, Lee JE, Lenzi R, Lahoti S, Vauthey JN, Janjan NA. Crane CH, et al. Semin Oncol. 2001 Jun;28(3 Suppl 10):25-33. doi: 10.1053/sonc.2001.22536. Semin Oncol. 2001. PMID: 11510031 Review.

• [Combined gemcitabine and radiotherapy].

  Mornex F. Mornex F. Bull Cancer. 2002 Aug;89 Spec No:S127-33. Bull Cancer. 2002. PMID: 12449044 Review. French.

Cited by

• The relation between deoxycytidine kinase activity and the radiosensitising effect of gemcitabine in eight different human tumour cell lines.

  Pauwels B, Korst AE, Pattyn GG, Lambrechts HA, Kamphuis JA, De Pooter CM, Peters GJ, Lardon F, Vermorken JB. Pauwels B, et al. BMC Cancer. 2006 May 30;6:142. doi: 10.1186/1471-2407-6-142. BMC Cancer. 2006. PMID: 16734894 Free PMC article.

• Effect of chemoradiotherapy with gemcitabine and cisplatin on locoregional control in patients with primary inoperable pancreatic cancer.

  Wilkowski R, Thoma M, Schauer R, Wagner A, Heinemann V. Wilkowski R, et al. World J Surg. 2004 Oct;28(10):1011-8. doi: 10.1007/s00268-004-7338-z. Epub 2004 Sep 29. World J Surg. 2004. PMID: 15573257

• A phase I study of cetuximab in combination with gemcitabine and radiation for locally advanced pancreatic cancer.

  Chakravarthy AB, Tsai CJ, O'Brien N, Lockhart AC, Chan E, Parikh A, Berlin JD, Merchant N. Chakravarthy AB, et al. Gastrointest Cancer Res. 2012 Jul;5(4):112-8. Gastrointest Cancer Res. 2012. PMID: 23077684 Free PMC article.

• Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer.

  Okusaka T, Ito Y, Ueno H, Ikeda M, Takezako Y, Morizane C, Kagami Y, Ikeda H. Okusaka T, et al. Br J Cancer. 2004 Aug 16;91(4):673-7. doi: 10.1038/sj.bjc.6602001. Br J Cancer. 2004. PMID: 15226765 Free PMC article. Clinical Trial.

• Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial.

  Loehrer PJ Sr, Feng Y, Cardenes H, Wagner L, Brell JM, Cella D, Flynn P, Ramanathan RK, Crane CH, Alberts SR, Benson AB 3rd. Loehrer PJ Sr, et al. J Clin Oncol. 2011 Nov 1;29(31):4105-12. doi: 10.1200/JCO.2011.34.8904. Epub 2011 Oct 3. J Clin Oncol. 2011. PMID: 21969502 Free PMC article. Clinical Trial.

References

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • Nature Publishing Group
  • PubMed Central

• Medical

  • MedlinePlus Health Information